Known targets — ChEMBL curated mechanism
FGFR3FLT1FLT3FLT4KDRKITPDGFRAPDGFRB
The experimentally established mechanism targets of Dovitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB known ✓ | P09619 | 17/20 | 0.84 |
| ▸ | KDR known ✓ | P35968 | 17/20 | 0.84 |
| ▸ | FLT1 known ✓ | P17948 | 4/20 | 0.84 |
| ▸ | FLT3 known ✓ | P36888 | 2/20 | 0.84 |
| ▸ | KIT known ✓ | P10721 | 1/20 | 0.84 |
| ▸ | PDGFRA known ✓ | P16234 | 1/20 | 0.84 |
| ▸ | FGFR3 known ✓ | P22607 | 1/20 | 0.84 |
| ▸ | FLT4 known ✓ | P35916 | 1/20 | 0.84 |
| ▸ | FGFR1 | P11362 | 19/20 | 0.84 |
| ▸ | LCK | P06239 | 2/20 | 0.84 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.84 |
| ▸ | PLK4 | O00444 | 1/20 | 0.84 |
| ▸ | STK25 | O00506 | 1/20 | 0.84 |
| ▸ | CIT | O14578 | 1/20 | 0.84 |
| ▸ | RIOK3 | O14730 | 1/20 | 0.84 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.84 |
| ▸ | GAK | O14976 | 1/20 | 0.84 |
| ▸ | CHUK | O15111 | 1/20 | 0.84 |
| ▸ | MUSK | O15146 | 1/20 | 0.84 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dovitinib SCHEMBL29435017 | 1.00 | FGFR1 (0.84) | FGFR1PDGFRBKDRFLT1LCK | |
| Dovitinib SCHEMBL29351344 | 1.00 | FGFR1 (0.84) | FGFR1PDGFRBKDRFLT1LCK | |
| Dovitinib SCHEMBL253137 | 0.99 | FGFR1 (0.86) | FGFR1PDGFRBKDRFLT1LCK | |
| Dovitinib SCHEMBL29358063 | 0.99 | FGFR1 (0.86) | FGFR1PDGFRBKDRFLT1LCK | |
| Dovitinib SCHEMBL29352167 | 0.99 | FGFR1 (0.86) | FGFR1PDGFRBKDRFLT1LCK | |
| Dovitinib SCHEMBL28897930 | 0.94 | FGFR1 (0.75) | FGFR1PDGFRBKDRFLT1LCK | |
| Dovitinib SCHEMBL945391 | 0.94 | FGFR1 (0.73) | FGFR1PDGFRBKDRFLT1LCK | |
| Dovitinib SCHEMBL946022 | 0.93 | FGFR1 (0.75) | FGFR1PDGFRBKDRFLT1LCK | |
| Dovitinib SCHEMBL248083 | 0.93 | FGFR1 (0.98) | FGFR1PDGFRBKDRFLT1LCK | |
| Dovitinib SCHEMBL172687 | 0.92 | FGFR1 (1.00) | FGFR1PDGFRBKDRFLT1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200289645-A1 | TREATMENTS AND METHODS FOR CONTROLLING HYPERTENSION | GEORGETOWN UNIVERSITY (US) | 2020-09-17 | — | — | US | claimed |
| CN-106943355-B | Pharmaceutical composition | 诺华股份有限公司 | 2020-09-01 | — | — | CN | claimed |
| EP-2588086-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 4-AMINO-5-FLUORO-3-[6-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL]-1H-QUINOLIN-2-ONE LACTATE MONOHYDRATE. | NOVARTIS AG (CH) | 2018-09-12 | — | — | EP | claimed |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| CN-119040247-B | Application of multi-weitinib lactate in up-regulating lactoferrin expression in cells | 北京三元食品股份有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-119040247-A | Application of multi-weitinib lactate in up-regulating lactoferrin expression in cells | 北京三元食品股份有限公司 | 2024-11-29 | — | — | CN | disclosed |
| EP-4452271-A1 | USE OF A FGFR3 TYROSINE KINASE INHIBITOR FOR THE TREATMENT OF FGFR-RELATED BONE REPAIR AND BONE FORMATION IMPAIRMENTS | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2024-10-30 | — | — | EP | disclosed |
| US-20240325396-A1 | METHODS FOR TREATING CANCER | Allarity Therapeutics, Inc. | 2024-10-03 | — | — | US | disclosed |
| US-20230241061-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FGFR3-RELATED COGNITIVE DEFICIT | INST NAT SANTE RECH MED (FR) | 2023-08-03 | — | — | US | disclosed |
| WO-2023117879-A1 | USE OF A FGFR3 TYROSINE KINASE INHIBITOR FOR THE TREATMENT OF FGFR-RELATED BONE REPAIR AND BONE FORMATION IMPAIRMENTS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2023-06-29 | — | — | WO | disclosed |
| EP-4164648-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FGFR3-RELATED COGNITIVE DEFICIT | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2023-04-19 | — | — | EP | disclosed |
| CN-106943355-B | Pharmaceutical composition | 诺华股份有限公司 | 2020-09-01 | — | — | CN | disclosed |
| EP-2588086-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 4-AMINO-5-FLUORO-3-[6-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL]-1H-QUINOLIN-2-ONE LACTATE MONOHYDRATE. | NOVARTIS AG (CH) | 2018-09-12 | — | — | EP | disclosed |
| US-9545402-B2 | Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-y1)-1H-benzimidazol-2-y1]-1H-quinolin-2-one lactate monohydrate | NOVARTIS AG (CH) | 2017-01-17 | — | — | US | disclosed |
| US-9545402-B2 | Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-y1)-1H-benzimidazol-2-y1]-1H-quinolin-2-one lactate monohydrate | NOVARTIS AG (CH) | 2017-01-17 | — | — | US | disclosed |
| EP-2588086-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING 4-AMINO-5-FLUORO-3-[6-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL]-1H-QUINOLIN-2-ONE LACTATE MONOHYDRATE. | Novartis AG (CH) | 2013-05-08 | — | — | EP | disclosed |
| CN-103068373-A | Pharmaceutical composition comprising 4-amino-5-fluoro-3- [6- (4-methylpiperazin-1-yl) -1H-benzimidazol-2-yl ] -1H-quinolin-2-one lactate monohydrate | NOVARTIS AG | 2013-04-24 | — | — | CN | disclosed |
| US-20130090344-A1 | Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-y1)-1H-benzimidazol-2-y1]-1H-quinolin-2-one lactate monohydrate | NOVARTIS AG (CH) | 2013-04-11 | — | — | US | disclosed |
| US-20130090344-A1 | Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-y1)-1H-benzimidazol-2-y1]-1H-quinolin-2-one lactate monohydrate | NOVARTIS AG (CH) | 2013-04-11 | — | — | US | disclosed |
| WO-2012001074-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING 4-AMINO-5-FLUORO-3-[6-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL]-1H-QUINOLIN-2-ONE LACTATE MONOHYDRATE. | NOVARTIS AG (CH) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240325396-A1 | METHODS FOR TREATING CANCER | TP53, KRAS, CDK4 | PDGFRB 321/4885KDR 107/4885FLT1 478/4885 |
| US-20130090344-A1 | Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-y1)-1H-benzimidazol-2-y1]-1H-quinolin-2-one lactate monohydrate | LCT, LDHA, HK1 | PDGFRB 3716/4885KDR 3569/4885FLT1 1744/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | PDGFRB 2435/4885KDR 4542/4885FLT1 4870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.